EUCTR2011-002259-32-LT进行中（未招募）不适用
A multicentre, double-blind, placebo-controlled, randomized trial to assess the efficacy and tolerability of two dosing regimens of AllerT, a combination of contiguous overlapping peptides derived from Bet v 1, in adult subjects allergic to birch pollen
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Anergis SA
- 入组人数
- 306
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men or women aged 18 to 55 years
- •2. Subjects presenting moderate to severe allergic rhinoconjunctivitis to birch pollen confirmed at screening by all of the following criteria:
- •a. Score of symptoms of the Rhinoconjunctivitis Symptom Score (RSS) = 12 during the two preceding birch pollen seasons based on subject’s interview by the investigator
- •b. Previous use of anti-allergy medications during the two preceding birch pollen seasons based on subject’s interview by the investigator
- •c. Positive SPT to birch pollen extract (wheal = 3 mm larger than the diluent control)
- •d. Positive specific IgE CAP test for Bet v 1 (= 0.7 kU/L)
- •3. Women of childbearing potential under continuous effective contraception during the treatment period
- •a. This includes: established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; true abstinence (periodic abstinence and withdrawal are not acceptable) or vasectomised male partner, provided that he is the sole partner of that subject.
- •4.Subjects having been informed and having provided signed consent for participating in the trial and willing to follow all planned trial assessments
- •Included subjects must not be entered more than once into the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 306
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
- •1. Men or women aged 18 to 55 years
- •2. Subjects presenting moderate to severe allergic rhinoconjunctivitis to birch pollen confirmed at screening by all of the following criteria:
- •a. Score of symptoms of the Rhinoconjunctivitis Symptom Score (RSS) = 12 during the two preceding birch pollen seasons based on subject’s interview by the investigator
- •b. Previous use of anti-allergy medications during the two preceding birch pollen seasons based on subject’s interview by the investigator
- •c. Positive SPT to birch pollen extract (wheal = 3 mm larger than the diluent control)
- •d. Positive specific IgE CAP test for Bet v 1 (= 0.7 kU/L)
- •3. Women of childbearing potential under continuous effective contraception during the treatment period
- •a. This includes: established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; true abstinence (periodic abstinence and withdrawal are not acceptable) or vasectomised male partner, provided that he is the sole partner of that subject.
- •4.Subjects having been informed and having provided signed consent for participating in the trial and willing to follow all planned trial assessments
- •Included subjects must not be entered more than once into the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 306
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Positive SPT to AllerT (wheal = 3 mm larger than the diluent control)
- •2. Received specific immunotherapy against:
- •a. Any allergen within five (5) years before the screening visit
- •b. Birch pollen or a tree pollen mix including birch pollen at any time before the screening visit
- •3. Clinical symptoms due to allergens other than birch pollen during the whole trial period (e.g. perennial allergies, allergies to other pollens with a season overlapping the birch pollen season)
- •4. Persistent non-controlled asthma; subjects with a Forced Expiratory Volume (FEV1) lower than 80% of predicted value (see FEV1 predicted and 80% of predicted values in Appendix 12.3) and/or subjects under chronic treatment for asthma. Subjects with seasonal asthma may be included.
- •5. History of severe anaphylactic reaction (grade 4 reaction as per the definitions given in Appendix 12.1)
- •6. History of any debilitating disease and/or severe medical condition able to influence the course of the trial or the ability of the subjects to fulfill the requirements of the trial
- •7. Any confirmed or suspected primary or secondary immunodeficiency condition, including human immunodeficiency virus (HIV) infection and asplenia
- •8. Pregnant or lactating women or women willing or intending to become pregnant during the trial
- •9. Suspected or known current alcohol or any drug abuse
- •10. Any other significant finding which, in the opinion of the investigator, would increase the risk of having an adverse outcome from participating in this protocol or of dropping out of the trial
- •11. Subjects intending to travel during the birch pollen season outside of the birch pollination area for more than seven consecutive days
- •12. Subjects unable or unwilling to record allergy symptoms and medications daily during the following birch pollen season using an electronic diary device
- •13. Subjects not covered by medical insurance
- •14. Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
- •15. Beta-blockers or ACE-inhibitors within four weeks prior to randomization, or planned to be used during the treatment period
- •16. Immunosuppressive medication within four weeks prior to randomization, or planned to be used during the trial period
- •17. Systemic or local antihistamines, oral or inhaled corticosteroids or under anti-depressant medication with antihistamine effect within two weeks prior to randomization
- •18. Use of any investigational or non-registered drug, vaccine or medical device within four weeks prior to randomization, or planned to be used during the trial period
- •1. Positive SPT to AllerT (wheal = 3 mm larger than the diluent control)
- •2. Received specific immunotherapy against:
- •a. Any allergen within five (5) years before the screening visit
- •b. Birch pollen or a tree pollen mix including birch pollen at any time before the screening visit
- •3. Clinical symptoms due to allergens other than birch pollen during the whole trial period (e.g. perennial allergies, allergies to other pollens with a season overlapping the birch pollen season)
- •4. Persistent non-controlled asthma; subjects with a Forced Expiratory Volume (FEV1) lower than 80% of predicted value (see FEV1 predicted and 80% of predicted values in Appendix 12.3) and/or subjects under chronic treatment for asthma. Subjects with seasonal asthma may be included.
- •5. History of severe anaphylactic reaction (grade 4 reaction as per the definitions given in Appendix 12.1)
- •6. History of any debilitating disease and/or severe medical condition able to influence the course of the trial or the ability of the subjects to fulfill the requirements of the trial
- •7. Any confirmed or suspected primary or secondary immunodeficiency condition, including human immunodeficiency virus (HIV) infection and asplenia
- •8. Pregnant or lactating women or women willing or intending to become pregnant during the trial
- •9. Suspected or known current alcohol or any drug abuse
- •10. Any other significant finding which, in the opinion of the investigator, would increase the risk of having an adverse outcome from participating in this protocol or of dropping out of the trial
- •11. Subjects intending to travel during the birch pollen season outside of the birch pollination area for more than seven consecutive days
- •12. Subjects unable or unwilling to record allergy symptoms and medications daily during the following birch pollen season using an electronic diary device
- •13. Subjects not covered by medical insurance
- •14. Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
- •15. Beta-blockers or ACE-inhibitors within four weeks prior to randomization, or planned to be used during the treatment period
- •16. Immunosuppressive medication within four weeks prior to randomization, or planned to be used during the trial period
- •17. Systemic or local antihistamines, oral or inhaled corticosteroids or under anti-depressant medication with antihistamine effect within two weeks prior to randomization
- •18. Use of any investigational or non-registered drug, vaccine or medical device within four weeks prior to randomization, or planned to be used during the trial period
研究者
相似试验
进行中（未招募）
不适用
Application of AllerT, a drug based on modified peptides of Bet V 1, in two different dosages to subjects suffering from birch pollen allergy to investigate the efficacy and the safety compared with a placeboDesensitization by Specific ImmunoTherapy (SIT) in subjects allergic to birch pollenMedDRA version: 14.1Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 10021428 - Immune system disordersEUCTR2011-002259-32-DKAnergis SA306
进行中（未招募）
不适用
Application of AllerT, a drug based on modified peptides of Bet V 1, in two different dosages to subjects suffering from birch pollen allergy to investigate the efficacy and the safety compared with a placeboEUCTR2011-002259-32-SEAnergis SA306
进行中（未招募）
不适用
Application of AllerT, a drug based on modified peptides of Bet V 1, in two different dosages to subjects suffering from birch pollen allergy to investigate the efficacy and the safety compared with a placeboDesensitization by Specific ImmunoTherapy (SIT) in subjects allergic to birch pollenMedDRA version: 15.0Level: LLTClassification code 10066093Term: Birch pollen allergySystem Organ Class: 10021428 - Immune system disordersEUCTR2011-002259-32-LVAnergis SA306
招募中
3 期
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With RemibrutinibJPRN-jRCT2031220499Hirano Takamitsu57
进行中（未招募）
1 期
Clinical study for the evaluation of the safety and efficacy of masitinib in patients suffering from mild to moderate Alzheimer's diseasemild to moderate Alzheimer’s diseaseMedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disordersEUCTR2010-021218-50-PLAB Science675